Research programme: gene editing based therapeutics - Casebia Therapeutics
Alternative Names: CRISPR/Cas9 gene editing therapies - Bayer-CRISPR TherapeuticsLatest Information Update: 28 May 2024
At a glance
- Originator Casebia Therapeutics
- Class Antihaemorrhagics; Antineoplastics; Cardiovascular therapies; Eye disorder therapies; Gene therapies
- Mechanism of Action Gene modulators; Gene transference; Immunogenetic modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Autoimmune disorders; Blindness; Cancer; Congenital heart defects; Haemophilia A; Retinitis pigmentosa; Severe combined immunodeficiency
Most Recent Events
- 28 May 2024 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA
- 28 May 2024 No recent reports of development identified for research development in Cancer in USA (Parenteral)
- 28 May 2024 No recent reports of development identified for research development in Haemophilia-A in USA